Influenza Vaccine Effectiveness Pre-pandemic among Adults Hospitalized with Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, and Older Adults.

2018–2019 2019–2020 CHF COPD elderly flu severity

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
08 Nov 2023
Historique:
received: 18 08 2023
revised: 30 10 2023
accepted: 06 11 2023
medline: 10 11 2023
pubmed: 10 11 2023
entrez: 10 11 2023
Statut: aheadofprint

Résumé

Data are limited about influenza vaccine effectiveness (VE) in the prevention of influenza-related hospitalizations in older adults and those with underlying high-risk comorbidities. We conducted a prospective test-negative case-control study at two US hospitals from October 2018-March 2020 among adults ≥50 years of age hospitalized with acute respiratory illnesses (ARIs) and adults ≥18 years admitted with congestive heart failure (CHF) or chronic obstructive pulmonary disease (COPD) exacerbations. Adults were eligible if they resided in 1 of 8 counties in metropolitan Atlanta, GA. Nasopharyngeal and oropharyngeal swabs were tested using BioFire® FilmArray® respiratory panel, and standard-of-care molecular results were included when available. Influenza vaccination history was determined from the Georgia vaccine registry and medical records. We used multivariable logistic regression to control for potential confounders and to determine 95% confidence intervals (CI). Among 3,090 eligible adults, 1562 (50.6%) were enrolled. Of the 1515 with influenza vaccination history available, 701 (46.2%) had received vaccination during that season. Influenza was identified in 37 (5.3%) vaccinated vs. 78 (9.6%) unvaccinated participants. After adjustment for age, race/ethnicity, immunosuppression, month, and season, pooled VE for any influenza-related hospitalization in the eligible study population was 63.1% (95% CI: 43.8, 75.8). Adjusted VE against influenza-related hospitalization for ARI in adults ≥50 years was 55.9% (29.9, 72.3) and adjusted VE against Influenza-related CHF/COPD exacerbation in adults ≥18 years was 80.3% (36.3, 93.9). Influenza vaccination was effective in preventing influenza-related hospitalizations in adults ≥50 years of age and those with CHF/COPD exacerbations during the 2018-2020 seasons.

Sections du résumé

BACKGROUND BACKGROUND
Data are limited about influenza vaccine effectiveness (VE) in the prevention of influenza-related hospitalizations in older adults and those with underlying high-risk comorbidities.
METHODS METHODS
We conducted a prospective test-negative case-control study at two US hospitals from October 2018-March 2020 among adults ≥50 years of age hospitalized with acute respiratory illnesses (ARIs) and adults ≥18 years admitted with congestive heart failure (CHF) or chronic obstructive pulmonary disease (COPD) exacerbations. Adults were eligible if they resided in 1 of 8 counties in metropolitan Atlanta, GA. Nasopharyngeal and oropharyngeal swabs were tested using BioFire® FilmArray® respiratory panel, and standard-of-care molecular results were included when available. Influenza vaccination history was determined from the Georgia vaccine registry and medical records. We used multivariable logistic regression to control for potential confounders and to determine 95% confidence intervals (CI).
RESULTS RESULTS
Among 3,090 eligible adults, 1562 (50.6%) were enrolled. Of the 1515 with influenza vaccination history available, 701 (46.2%) had received vaccination during that season. Influenza was identified in 37 (5.3%) vaccinated vs. 78 (9.6%) unvaccinated participants. After adjustment for age, race/ethnicity, immunosuppression, month, and season, pooled VE for any influenza-related hospitalization in the eligible study population was 63.1% (95% CI: 43.8, 75.8). Adjusted VE against influenza-related hospitalization for ARI in adults ≥50 years was 55.9% (29.9, 72.3) and adjusted VE against Influenza-related CHF/COPD exacerbation in adults ≥18 years was 80.3% (36.3, 93.9).
CONCLUSIONS CONCLUSIONS
Influenza vaccination was effective in preventing influenza-related hospitalizations in adults ≥50 years of age and those with CHF/COPD exacerbations during the 2018-2020 seasons.

Identifiants

pubmed: 37946601
pii: 7381063
doi: 10.1093/cid/ciad679
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Ashley Tippett (A)

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.

Gabby Ess (G)

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.

Laila Hussaini (L)

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.

Olivia Reese (O)

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.

Luis Salazar (L)

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.

Mary Kelly (M)

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.

Meg Taylor (M)

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.

Caroline Ciric (C)

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.

Amy Keane (A)

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.

Andrew Cheng (A)

Department of Medicine, Hope Clinic, Emory University School of Medicine, Atlanta, Georgia, USA.

Theda Gibson (T)

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.

Wensheng Li (W)

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.

Hui-Mien Hsiao (HM)

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.

Laurel Bristow (L)

Department of Medicine, Hope Clinic, Emory University School of Medicine, Atlanta, Georgia, USA.

Kieffer Hellmeister (K)

Department of Medicine, Hope Clinic, Emory University School of Medicine, Atlanta, Georgia, USA.

Zayna Al-Husein (Z)

Department of Medicine, Hope Clinic, Emory University School of Medicine, Atlanta, Georgia, USA.

Robin Hubler (R)

Pfizer, Inc.

Qing Liu (Q)

Pfizer, Inc.

Satoshi Kamidani (S)

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

Carol Kao (C)

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

Inci Yildirim (I)

Department of Pediatrics (Infectious Diseases), Yale-New Haven Hospital, New Haven, CT, USA.
Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Yale Institute for Global Health, Yale School of Public Health, New Haven, CT, USA.
Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA.

Nadine Rouphael (N)

Department of Medicine, Hope Clinic, Emory University School of Medicine, Atlanta, Georgia, USA.

Christina A Rostad (CA)

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

Evan J Anderson (EJ)

Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Department of Medicine, Hope Clinic, Emory University School of Medicine, Atlanta, Georgia, USA.

Classifications MeSH